Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib with or without local ablation in EGFR-mutant advanced NSCLC with sustained stable disease
ChiCTR2600134191Phase 2Not yet recruiting
- Sponsor
- Chengdu Seventh People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Chengdu Seventh People's Hospital. Primary endpoint: Progression-Free Survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600134191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134191.